4336-v 0.5 mg | 145.00 EUR
Thr – Glu – Pro – Gly – Leu – Glu – Glu – Val – Gly – Glu – Ile – Glu – Gln – Lys – Gln – Leu – Gln
Synthetic Product (Ammonium Form)
The purity is guaranteed to be higher than 99% by HPLC
Nociceptin Action Blocking Peptide
A peptide that blocks nociceptin action is found from the nociceptin precursor
Nociceptin [Nature, 377, 532 (1995)] / Orphanin FQ [Science, 270, 792 (1995)], is an endogenous ligand for the orphan opioid-like receptor. Nociceptin induces both allodynia (pain resulting from a non-noxious stimulus to normal skin) and hyperalgesia when administered intrathecally [Brit. J. Pharmacol., 121, 401 (1997)].
Bovine nocistatin: Nocistatin, a 17-residue peptide, which is encoded upstream from nociceptin in the cDNA sequence, was isolated from bovine brain [Nature, 392 , 286 (1998)]. Surprisingly, these co-translated peptides show opposite biological effects: nocistatin blocks the nociceptin induced allodynia and hyperalgesia. Nocistatin also attenuated pain responses evoked by prostaglandin E2. Nocistatin binds to the membrane of mouse brain and spinal cord with a high affinity but does not bind to the nociceptin receptor. Nocistatin and nociceptin may play opposite roles in pain transmission. The finding of nocistatin should be of great interest to the field of pain research and opioid pharmacology, and may lead to the design of a novel analgesic devoid of the addiction and dependence seen in morphine.
- E. Okuda-Ashitaka, T. Minami, S. Tachibana, Y. Yoshihara, Y. Nishiuchi, T. Kimura and S. Ito, Nature, 392, 286 (1998) (Original)
- B. Nicol, D.J. Lambert, D.J. Rowbothan, E. Okuda-Ashitaka, S. Ito, D. Smart and A.T. McKnight, Eur. J. Pharmacol, 356, R1 (1998) (Pharmacol.)
- T. Nakagawa, M. Kaneko, S. Inamura and M. Sato, Neurosci. Lett., 265, 64 (1999) (Pharmacol.)